Why is Moderna Substantially Expanding Manufacturing Capacity Despite Current Low Demand For Their “Poison?”

Moderna is substantially expanding manufacturing capacity, despite low demand for their mRNA “poison.” according to Pharma and medical device research and development executive Sasha Latypova. In December 2022 the government announced that the UK had cemented a 10-year-partnership with Moderna in “major boost for vaccines and research” with a plan to build a “state-of-the-art vaccine manufacturing centre with the ability to produce up to 250 million vaccines a year.”

Apparently they are building them in many countries too, with much more capacity than they had for covid shots’ according to Sasha who claims that according to her inside source at Moderna, the new capacity is not for the flu vaccine. Her assessment is that “The ‘Blob is planning something “big”

Sasha Latypova has listed the countries that will be home to a Moderna manufacturing centre.

Canada:

Moderna says construction of its new mRNA vaccine factory in Laval, Que. will begin later this year, with production expected to begin by the end of 2024. It will be the pharmaceutical giant’s first manufacturing facility outside the United States and cost an estimated $180 million to construct.”

Australia:

“US biotech company Moderna has reached an in-principle agreement to build an mRNA vaccine manufacturing facility in Victoria. It will become the first mRNA manufacturing facility in the Southern Hemisphere. Moderna expects to produce up to 100 million vaccine doses each year in Australia.”

Read more: Why is Moderna Substantially Expanding Manufacturing Capacity Despite Current Low Demand For Their “Poison?”


Leave a Reply

Your email address will not be published. Required fields are marked *